Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Michon

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
Journal of Medical Genetics|August 1, 1996
No founder effect in three novel Alzheimer's disease families with APP 717 Val-->Ile mutation. Clerget-darpoux. French Alzheimer's Disease Study GroupD Campion, A Brice, D Hannequin, et al.
EJNMMI Reports|July 7, 2025
Lung shunting and radiation pneumonitis after holmium-166 TARE: a case studyMeike W M van Wijk, Marcel J R Janssen, Mark J Arntz, et al.
European Journal of Human Genetics : EJHG|September 12, 2000
APOE promoter polymorphisms do not confer independent risk for Alzheimer's disease in a French populationL Zurutuza, P Verpillat, G Raux, et al.
Neuroreport|July 8, 1996
A novel presenilin 1 mutation resulting in familial Alzheimer's disease with an onset age of 29 yearsD Campion, A Brice, C Dumanchin, et al.
American Journal of Human Genetics|August 12, 1999
Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrumD Campion, C Dumanchin, D Hannequin, et al.
Molecular Psychiatry|April 5, 2012
High frequency of potentially pathogenic SORL1 mutations in autosomal dominant early-onset Alzheimer diseaseC Pottier, D Hannequin, S Coutant, et al.
American Journal of Human Genetics|February 1, 1997
Apolipoprotein E and Alzheimer disease: genotype-specific risks by age and sexH Bickeböller, D Campion, A Brice, et al.
Lupus|March 31, 2017
Cessation of oral anticoagulants in antiphospholipid syndromeC Comarmond, P Jego, C Veyssier-Belot, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Journal of Medical Genetics|August 1, 1996
No founder effect in three novel Alzheimer's disease families with APP 717 Val-->Ile mutation. Clerget-darpoux. French Alzheimer's Disease Study GroupD Campion, A Brice, D Hannequin, et al.
EJNMMI Reports|July 7, 2025
Lung shunting and radiation pneumonitis after holmium-166 TARE: a case studyMeike W M van Wijk, Marcel J R Janssen, Mark J Arntz, et al.
European Journal of Human Genetics : EJHG|September 12, 2000
APOE promoter polymorphisms do not confer independent risk for Alzheimer's disease in a French populationL Zurutuza, P Verpillat, G Raux, et al.
Neuroreport|July 8, 1996
A novel presenilin 1 mutation resulting in familial Alzheimer's disease with an onset age of 29 yearsD Campion, A Brice, C Dumanchin, et al.
American Journal of Human Genetics|August 12, 1999
Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrumD Campion, C Dumanchin, D Hannequin, et al.
Molecular Psychiatry|April 5, 2012
High frequency of potentially pathogenic SORL1 mutations in autosomal dominant early-onset Alzheimer diseaseC Pottier, D Hannequin, S Coutant, et al.
American Journal of Human Genetics|February 1, 1997
Apolipoprotein E and Alzheimer disease: genotype-specific risks by age and sexH Bickeböller, D Campion, A Brice, et al.
Lupus|March 31, 2017
Cessation of oral anticoagulants in antiphospholipid syndromeC Comarmond, P Jego, C Veyssier-Belot, et al.
Pageof 6